It Is Time to Harmonize the Design and Conduct of Clinical Trials in Metastatic Hormone-sensitive Prostate Cancer

Affiliations

¹ Princess Margaret Cancer Centre, Toronto, Ontario, Canada.
² Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA. Electronic address: christopher_sweeney@dfci.harvard.edu.

Editorial

Srikala S Sridhar et al. Eur Urol. 2016 Aug.

. 2016 Aug;70(2):263-4.

doi: 10.1016/j.eururo.2015.11.025. Epub 2015 Dec 9.

¹ Princess Margaret Cancer Centre, Toronto, Ontario, Canada.
² Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA. Electronic address: christopher_sweeney@dfci.harvard.edu.

No abstract available

Comment on

Androgen Deprivation Therapy (ADT) Plus Docetaxel Versus ADT Alone in Metastatic Non castrate Prostate Cancer: Impact of Metastatic Burden and Long-term Survival Analysis of the Randomized Phase 3 GETUG-AFU15 Trial.
Gravis G, Boher JM, Joly F, Soulié M, Albiges L, Priou F, Latorzeff I, Delva R, Krakowski I, Laguerre B, Rolland F, Théodore C, Deplanque G, Ferrero JM, Culine S, Mourey L, Beuzeboc P, Habibian M, Oudard S, Fizazi K; GETUG. Gravis G, et al. Eur Urol. 2016 Aug;70(2):256-62. doi: 10.1016/j.eururo.2015.11.005. Epub 2015 Nov 21. Eur Urol. 2016. PMID: 26610858 Clinical Trial.